Buy & Sell Hologic, Inc. (HOLX) – Hologic, Inc. Price Today
Key Stats
- $16.97BMarket Cap
- HealthSector
- -0.18%3M Drawdown
- $17.12BEnterprise Value
- -Dividend Yield
- 60 daysTypical Hold Time
Hologic, Inc. (HOLX) is currently valued at a market capitalization of $16.97B, with an enterprise value of $17.12B. Over the past 52 weeks, Hologic, Inc. has traded between a low of $62.01 and a high of $76.01, highlighting its annual price range. Over the past three months, Hologic, Inc. has recorded a drawdown of -0.18%, reflecting recent price volatility. On average, investors hold Hologic, Inc. for approximately 60 days, indicating typical investor behavior on the platform.
About Hologic, Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (64% of total sales, boosted by pandemic), breast health (21% of sales, suppressed by pandemic), surgical (12%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (75%), followed by Europe (16%), Asia (6%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Most Recent News
US government buys 10% stake in mining firms, signaling a new strategic investment trend.
In early 2026, the US government began acquiring stakes in American mining companies, including a 10% share in USA Rare Earth to support critical mineral projects. This move follows similar investments in Lithium Americas and Trilogy Metals, which sa...
FDA approves Sanofi's Tzield as first disease-modifying therapy for stage 3 type 1 diabetes in children.
The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This is the first disease-modifying therapy aimed at delaying the decline of insulin produc...
FDA approves Sanofi's Tzield as first disease-modifying therapy for newly diagnosed stage 3 type 1 diabetes in children.
The FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). Tzield slows the decline of the body's insulin production by targeting the autoimmune process c...